4 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 8 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 6 | Completed 4, Recruiting 1, Terminated 1 |
Follow B-cell Malignancies: new trials by email Literature Review of B-cell Malignancies trials Research Report on B-cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Emavusertib, Zanubrutinib - Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | Curis, Inc. | 108 | 2026-04-23 | 2026-06-12 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. AZD5492 - B-cell Malignancies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 174 | 2024-09-18 | 2026-09-30 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies | Phase 2 | Active not recruiting | Incyte Corporation | 112 | 2020-08-03 | 2026-06-25 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Nivolumab, Epacadostat, Chemotherapy - B-cell Malignancies, Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Incyte Corporation | 307 | 2014-11-26 | 2025-08-14 |
| Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Zanubrutinib - B-cell Malignancies | Phase 1 / Phase 2 | Completed | BeiGene | 385 | 2014-09-04 | 2022-04-28 |
| A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies MEDI-551, Rituximab - B-cell Malignancies, Cancer | Phase 1 / Phase 2 | Completed | MedImmune LLC | 136 | 2010-04-16 | 2020-05-13 |
Leukemia, B-Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Colorectal Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Hematologic Diseases (4) · Leukemia (3) · Leukemia, Lymphoid (3) · Chronic Disease (2) · Disease Attributes (2) · Lymphoma (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Rituximab (2) · itacitinib (2) · parsaclisib (2) · zanubrutinib (2) · Carboplatin (1) · Drug Therapy (1) · Etoposide (1) · INCB039110 (1) · Ifosfamide (1) · Nivolumab (1) · epacadostat (1) · ibrutinib (1) · inebilizumab (1) · ruxolitinib (1)
Incyte Corporation (3) · AstraZeneca (1) · BeiGene (1) · Curis, Inc. (1) · MedImmune LLC (1) · Shenzhen Geno-Immune Medical Institute (1)
United States (7) · Italy (5) · Spain (4) · United Kingdom (3) · Australia (2) · Belgium (2) · Canada (2) · China (2) · Denmark (2) · France (2) · Japan (2) · South Korea (2) · Austria (1) · Czechia (1) · Germany (1)
Claudia Corrado, M.D. (1) · Lance Leopold (1) · Lung-Ji Chang, PhD (1)
PMID 30444200, PMID 30803990, PMID 34152395, PMID 35390135, PMID 35900694, PMID 38502198, PMID 38775302, PMID 39563886
2016 (2), 2009 (1), 2019 (1), 2025 (1)